Findings

What do systematic reviews say?

5 questions · 13 findings · 1 reviews · Oral Health · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 9 · 69.2%Very low 4 · 30.8%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

9 findings from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Skin toxicity (lapatinib, all grades)
RR 2.02 [1.23, 3.32]
1 study · 67 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Gastrointestinal complaints (gefitinib, all grades)
RR 1.04 [0.98, 1.11]
1 study · 226 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Gastrointestinal complaints (lapatinib, all grades)
RR 15.53 [2.18, 110.55]
1 study · 67 participants
GRADE not reported

Show 6 more findings

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Skin toxicity (erlotinib, all grades)
RR 6.57 [3.60, 12.00]
1 study · 191 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Mucositis (grades >=3)
RR 1.22 [0.96, 1.56]
2 studies · 286 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Mucositis (all grades)
RR 1.03 [0.94, 1.11]
2 studies · 286 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Skin toxicity (gefitinib, all grades)
RR 1.03 [0.82, 1.28]
2 studies · 286 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Gastrointestinal complaints (grades >=3, pooled)
RR 1.11 [0.83, 1.49]
3 studies · 484 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Skin toxicity (grades >=3, pooled)
RR 1.25 [0.54, 2.88]
4 studies · 544 participants
GRADE not reported

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.80 [0.51, 1.28]
2 studies · 271 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.99 [0.62, 1.57]
2 studies · 271 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes disease-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Gefitinib + radiotherapy (oral cavity)
HR 1.51 [0.61, 3.71]
1 study · 60 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.89 [0.53, 1.49]
2 studies · 271 participants
Very low